Pharma's chain of custody model is migrating into food and consumer goods — and becoming a cross-industry differentiator.
|Videos|February 4, 2022
Pharmaceutical Executive Roundtable: Future Shaping in Sales and Marketing: Preventative Medicine, Population Health, and Branding
In this segment, members of the panel discuss how to make medicine more accessible to the broader population. And how does the industry address affordability?
Advertisement
Advertisement
Related to this article
Pharma logistics are overqualified by design — and how agentic AI can now optimize across thousands of lanes in days, not months.
Pharma AI adoption fails not because of the technology — but because organizations deploy tools before they're ready to use them.
CORXEL’s Dr. Bo Liang on why GLP-1 therapies are a broader chronic disease platform — not just obesity drugs — with benefits across cardiovascular, renal, and metabolic disease.
Why GLP-1s achieving bariatric surgery-level efficacy is the field's most surprising advancement of the past decade.
CORXEL’s Dr. Bo Liang on why small molecule oral therapies will be the long-term winners in a GLP-1 market driven by consumer preference.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: TRexBio & Retension Pharmaceuticals Announce IPO Pricing
2
FDA Approves Tecentriq for Stage III dMMR Colon Cancer
3
The Most Important Lessons Learned from Building CGT Supply Chains: LogiPharma 2026
4
Naoki Okamura: Post-Patent Plan and Purpose
5